Physician profile
Gary Cohen
NPI 1346264413
$2,779.12
in general payments reported to CMS, 2019-2025
32 companies · $910 in 2025
The $910 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $271 · 2021: $60.99 · 2023: $29.56 · 2024: $569 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,508.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $623.92 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $220.15 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Astellas Pharma US INC | $201.91 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $197.46 | 2019-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Lilly USA, LLC | $147.12 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.36 | 2019-2025 | Xifaxan |
| Pfizer INC. | $144.79 | 2019-2025 | |
| Abbott Laboratories | $116.63 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $113.19 | 2019-2025 | |
| Exact Sciences Corporation | $105.09 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $72.82 | 2019-2025 | Arexvy, Shingrix |
| Abbvie INC. | $60.99 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $59.38 | 2025 | Uptravi, Opsumit |
| Amarin Pharma, INC. | $56.49 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $56.46 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $53.69 | 2024-2025 | Korlym |
| Eisai INC. | $52.75 | 2025 | |
| Janssen Pharmaceuticals, INC | $49.91 | 2019-2020 | |
| Ardelyx, INC. | $46.37 | 2024-2025 | Ibsrela |
| Genentech USA, INC. | $32.27 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.97 | 2020-2024 | Trintellix |
| Avanir Pharmaceuticals, INC. | $28.30 | 2019-2020 | |
| Dexcom, INC. | $26.97 | 2024 | Dexcom G6 Transmitter |
| Seqirus USA INC | $23.37 | 2025 | Fluad, Flucelvax |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.56 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.56 | 2025 | Nuzyra |
| Currax Pharmaceuticals LLC | $14.48 | 2024 | Contrave |
| Watermark Medical, INC. | $14.36 | 2024 | |
| Novartis Pharmaceuticals Corporation | $13.33 | 2019 | |
| Merck Sharp & Dohme LLC | $12.91 | 2019 | |
| Hikma Pharmaceuticals USA | $12.52 | 2019 | |
| Scilex Pharmaceuticals INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.